Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

Inclusion Criteria:

• Provision of consent

• ECOG performance status 0-2

• Patients with confirmed (per standard disease specific diagnostic criteria),relapsed or refractory haematological malignancies (NHL, MM and AML)

• Must have previously received standard therapy

• Adequate organ function

Exclusion Criteria:

• Intervention with any chemotherapy, investigational agents or other anti-cancerdrugs within 14 days or 5 half-lives of the first dose

• Major surgical procedure or significant traumatic injury within 4 weeks of the firstdose of study treatment

• Strong inhibitors of CYP3A4 or CYP3A4 substrates with a narrow therapeutic rangetaken within 2 weeks of the first dose of study treatment

• Strong inducers of CYP3A4 within 4 weeks of the first dose of study treatment

• Patients should discontinue statins prior to starting study treatment

• CYP2C8 substrates with a narrow therapeutic range taken within 2 weeks of the firstdose of study treatment

• Any unresolved reversible toxicities from prior therapy >CTCAE grade 1 at the timeof starting study treatment (except alopecia and grade 2 neuropathy)

• Any evidence of severe or uncontrolled systemic diseases

• Any known uncontrolled inter-current illness

• QTcF prolongation (> 470 msec)